September 24, 2024 01:12 PM EDTUpdated 04:07 PM
Pharma
Law

Fed­er­al judge rules against Re­gen­eron's at­tempt to halt Am­gen from launch­ing Eylea biosim­i­lar

Katherine Lewin

News Reporter

Re­gen­eron’s stock $REGN dipped about 4% on Tues­day fol­low­ing a loss in its le­gal bat­tle with Am­gen over com­peti­tors to its block­buster eye treat­ment Eylea …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times